Floatz logo

Irinotecan

Malignant Glioma

Kailin Yang, MD, PhDSmall moleculePhase 2Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

108 Active assets in the Malignant Glioma cohort.

Asset / SponsorPhaseRating
Marizomib
Aadi Bioscience, Inc.
Phase 2BB
Valproic Acid
Virginia Commonwealth University
Phase 2BB
Valaciclovir
Trogenix ltd
Phase 2BB
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE
Oblato, Inc.
Phase 2BB
cc-5013
M.D. Anderson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →